Skip to content
lunerievidence engine
Sign inCreate free account

02Research · Supplement

Resveratrol

Measured against the 58-marker panel. Human studies found an effect on 19, no change in 10 and conflicting results on 11; 18 have no result yet.

Most studied for

metabolic_syndrome_insulin_resistance_mitochondrial_activation

  • Supported 19
  • No effect 10
  • Conflicting 11
  • No result yet 18
BOverall evidence grade
925Studies tracked
127Meta-analyses
333Randomized trials

01Read first

Who should be careful

From the dossier's safety review: 13 cautions and 13 interactions, 5 rated serious. They summarize research and labels; they are not advice for you.

Cautions13

  • SeriousPregnancyGrade C

    Resveratrol is a phytoestrogen (ERα/ERβ partial agonist/antagonist) that may disrupt fetal endocrine development. Corpus contains 187 pregnancy-related studies documenting risk investigation, not established safety.

  • SeriousSolid organ transplant patients on calcineurin inhibitors (cyclosporine, tacrolimus)Grade C

    Resveratrol inhibits P-gp and CYP3A4, both critical for cyclosporine and tacrolimus metabolism and elimination. Concentration increases of these narrow-TI drugs risk nephrotoxicity, neurotoxicity, and graft rejection events.

  • SeriousHormone-sensitive cancers (ER+ breast cancer, endometrial cancer)Grade D

    Resveratrol acts as a phytoestrogen with ERα/ERβ partial agonism at low concentrations and partial antagonism at higher concentrations. In estrogen receptor-positive cancers, partial agonism could theoretically stimulate tumor proliferation.

  • ModeratePre-existing hypotension or postural hypotensionGrade B

    Resveratrol reduces blood pressure via eNOS-mediated vasodilation and natriuresis (−3.7 to −5.8 mmHg SBP in MAs). In patients with pre-existing hypotension or on multiple antihypertensives, additional BP reduction may cause symptomatic hypotension, falls, and syncope.

Show 9 more

  • ModeratePre-surgical / Perioperative periodGrade C

    Resveratrol inhibits platelet aggregation via COX-1/COX-2 and thromboxane A2 suppression. Antiplatelet activity increases intraoperative and postoperative bleeding risk, particularly when combined with surgical anticoagulants or antiplatelet protocols.

  • ModerateActive bleeding disorders or ongoing anticoagulation therapyGrade C

    Resveratrol's antiplatelet (COX inhibition, thromboxane A2 suppression) and potential anticoagulant (CYP2C9 inhibition of warfarin metabolism) effects combine to increase hemorrhagic risk.

  • ModerateLactation / BreastfeedingGrade D

    Resveratrol and metabolites likely transfer into breast milk based on lipophilicity and high protein binding (~93–99%). Phytoestrogenic exposure to nursing infant is unknown.

  • ModerateModerate to severe hepatic impairment (Child-Pugh B/C)Grade D

    Resveratrol undergoes extensive hepatic Phase II metabolism (UGT1A1, UGT1A9, SULT1A1). Hepatic impairment reduces conjugation capacity, increasing free resveratrol exposure and prolonging half-life.

  • ModeratePediatric population (under 18 years)Grade D

    No safety, pharmacokinetic, or efficacy data exist for resveratrol in pediatric populations. Phytoestrogenic effects are of particular concern during puberty and growth phases, with potential for endocrine disruption at critical developmental windows.

  • ModerateBiliary obstructionGrade D

    Biliary obstruction impairs excretion of glucuronide conjugates (major resveratrol metabolites). Conjugate accumulation may prolong pharmacological effects and alter the interaction profile.

  • MinorConcurrent structured aerobic exercise training programsGrade B

    Resveratrol's AMPK/SIRT1 activation overlaps with exercise signaling pathways. Multiple RCTs (Gliemann 2013, Olesen 2013) demonstrate attenuation of exercise-induced cardiovascular and metabolic adaptations in older adults.

  • MinorActive GI mucosal disease (active peptic ulcer, active IBD flare)Grade C

    Resveratrol has antiplatelet activity (COX inhibition) that may impair gastric mucosal protection, similar to NSAIDs.

  • MinorSevere renal impairment (eGFR <30 mL/min/1.73m²)Grade D

    Approximately 40% of resveratrol metabolites are renally excreted as sulfate conjugates. Severe renal impairment may result in conjugate accumulation.

Interactions13

  • SeriousCyclosporineGrade C

    (1) P-gp inhibition reduces cyclosporine intestinal efflux, increasing oral bioavailability; (2) CYP3A4 inhibition (Ki 6–26 μM) reduces hepatic cyclosporine metabolism.

  • SeriousTacrolimusGrade C

    P-gp and CYP3A4 inhibition by resveratrol reduces tacrolimus clearance. Extremely narrow therapeutic index (target trough 5–15 ng/mL).

  • ModerateWarfarinGrade C

    Dual: (1) CYP2C9 inhibition (Ki 30–100 μM) reduces warfarin S-enantiomer metabolism, elevating plasma anticoagulant effect; (2) COX-1/COX-2 inhibition and antiplatelet activity add pharmacodynamic bleeding risk

  • ModerateSimvastatin / AtorvastatinGrade C

    CYP3A4 inhibition increases plasma levels of CYP3A4-metabolized statins. P-gp inhibition may additionally reduce first-pass intestinal efflux.

Show 9 more

  • ModerateDigoxinGrade C

    P-gp inhibition reduces digoxin renal tubular efflux and intestinal elimination, increasing digoxin plasma levels.

  • ModerateAntiplatelet agents (aspirin, clopidogrel, ticagrelor)Grade C

    Resveratrol inhibits COX-1/COX-2 and thromboxane A2 synthesis, providing additive antiplatelet activity.

  • ModerateCYP1A2 substrates with narrow therapeutic index (theophylline, clozapine, tizanidine)Grade C

    Resveratrol inhibits CYP1A2 (Ki 21–38 μM).

  • ModerateMidazolam (CYP3A4 probe substrate)Grade C

    CYP3A4 inhibition reduces midazolam metabolism, potentially prolonging sedation.

  • MinorMetforminGrade B

    Pharmacodynamic synergism: both activate AMPK and improve insulin sensitivity. No significant pharmacokinetic interaction (metformin not CYP-metabolized.

  • MinorAntihypertensive drugs (ACE inhibitors, ARBs, beta-blockers, calcium channel blockers)Grade B

    Pharmacodynamic additive blood pressure lowering via eNOS/NO-mediated vasodilation and natriuresis.

  • MinorLosartanGrade C

    (1) CYP2C9 inhibition reduces losartan bioactivation to E-3174; (2) Pharmacodynamic additive BP lowering

  • MinorKetoconazole / ItraconazoleGrade C

    CYP3A4 inhibition by azoles may increase free resveratrol exposure. Both are also P-gp inhibitors.

  • MinorQT-prolonging drugs (amiodarone, sotalol, quinolone antibiotics, antipsychotics)Grade D

    Theoretical pharmacodynamic additive QT prolongation based on preclinical cardiac ion channel data.

02What it moves

40 markers studied

One row per marker on the panel that human studies measured. Open a row for the direction, who was studied, and the papers.

Read with this in mind

Resveratrol's cardiometabolic effects (glucose, insulin, BP, TG, CRP) are substantially larger or exclusively present in populations with metabolic disease (T2DM, obesity, MetS, NAFLD) and frequently null in healthy, lean, normoglycemic individuals.

Resveratrol's anti-inflammatory effects on CRP are contested.

Resveratrol's effects on LDL, HDL, and total cholesterol are inconsistent and frequently null.

Blood sugar4 of 4 studied

HbA1cLowersGrade A

Resveratrol lowers HbA1c.

Meta-analysis or review · Small effect · 26 studies linked

Studied in: T2DM, Prediabetes, Adults

Not assessed in timmers_2011 (30-day intervention too short for HbA1c change)

Open the HbA1c page →Check a claim about this →
Fasting glucoseMixed resultsGrade B

Studies of Resveratrol and fasting glucose disagree.

Meta-analysis or review · Small to moderate effect · 2 studies linked

Studied in: Obese, T2DM, Metabolic syndrome, Adults

NULL finding. Mechanistically expected floor effect in normoglycemia. Confirms fasting glucose lowering is specific to dysglycemic/T2DM populations. Does not undermine existing grade A MA evidence in T2DM.

Open the Fasting glucose page →Check a claim about this →
Fasting insulinMixed resultsGrade B

Studies of Resveratrol and fasting insulin disagree.

Meta-analysis or review · Small to moderate effect · 2 studies linked

Studied in: Obese, T2DM, Insulin resistant, Adults

NULL finding. Insulin sensitization appears population-specific (insulin-resistant/T2DM subjects).

Open the Fasting insulin page →Check a claim about this →
HOMA-IRMixed resultsGrade A

Studies of Resveratrol and HOMA-IR disagree.

Meta-analysis or review · Small to moderate effect · 33 studies linked

Studied in: Obese, T2DM, Metabolic syndrome, Dyslipidemia

NULL finding. Consistent with fasting_insulin null. HOMA-IR improvement limited to insulin-resistant populations.

Open the HOMA-IR page →Check a claim about this →

Lipids5 of 6 studied

LDL-CNo changeGrade A

Studies of Resveratrol found no change in LDL-C.

Meta-analysis or review · Negligible effect · 46 studies linked

Studied in: Mixed, Adults, Dyslipidemia, Normoglycemic

Majority of MAs show non-significant LDL effect. zhou_2023 confirms null at all doses. See ldl_cholesterol entry for detail. Merged: ldl_c and ldl_cholesterol refer to same biomarker.

Open the LDL-C page →Check a claim about this →
HDL-CNo changeGrade A

Studies of Resveratrol found no change in HDL-C.

Meta-analysis or review · Negligible effect · 37 studies linked

Studied in: Mixed, Adults, Dyslipidemia, Normoglycemic

MAs generally show no significant HDL effect. zhou_2023 confirms null. See hdl_cholesterol entry. Merged.

Open the HDL-C page →Check a claim about this →
TriglyceridesMixed resultsGrade A

Studies of Resveratrol and triglycerides disagree.

Meta-analysis or review · Small effect · 53 studies linked

Studied in: Obese, Metabolic syndrome, Hypertriglyceridemia, Dyslipidemia

See triglycerides entry for detailed analysis. Merged: tg and triglycerides refer to same biomarker.

Open the Triglycerides page →Check a claim about this →
Total cholesterolNo changeGrade A

Studies of Resveratrol found no change in total cholesterol.

Meta-analysis or review · 41 studies linked

Studied in: Mixed, Adults, Dyslipidemia, Normoglycemic

See total_cholesterol entry for detailed analysis. Merged: TC and total_cholesterol refer to same biomarker.

Open the Total cholesterol page →Check a claim about this →
ApoBNo changeGrade B

Studies of Resveratrol found no change in ApoB.

Human trials · Negligible effect · 3 studies linked

Studied in: Dyslipidemia, Normoglycemic, Chinese adults

zhou_2023 reports NS at all doses. 6 corpus studies mention ApoB. See apolipoprotein_b entry. Merged.

Open the ApoB page →Check a claim about this →

Inflammation4 of 5 studied

hs-CRPMixed resultsGrade A

Studies of Resveratrol and hs-CRP disagree.

Meta-analysis or review · 43 studies linked

Studied in: Mixed, Adults, Inflammatory conditions

See pc_rsv_002 for population caveat.

Open the hs-CRP page →Check a claim about this →
IL-6Mixed resultsGrade A

Studies of Resveratrol and IL-6 disagree.

Meta-analysis or review · 60 studies linked

Studied in: Mixed, Adults

See il6 entry for detail. Merged: il_6 and il6 refer to same biomarker.

Open the IL-6 page →Check a claim about this →
TNF-αLowersGrade A

Resveratrol lowers TNF-α.

Meta-analysis or review · Small effect · 51 studies linked

Studied in: Obese, Metabolic syndrome, Adults

timmers_2011: -1.01 pg/mL (p=0.04). 783 corpus studies. See tnf_alpha entry for detail. Merged: tnf_a and tnf_alpha refer to same biomarker.

Open the TNF-α page →Check a claim about this →
FibrinogenNo changeGrade A

Studies of Resveratrol found no change in fibrinogen.

Meta-analysis or review · 2 studies linked

Studied in: Adults

11 corpus studies. No extracted RCT outcome data. Theoretical decrease via anti-inflammatory mechanisms but unconfirmed.

Open the Fibrinogen page →Check a claim about this →

Liver5 of 6 studied

ALTLowersGrade A

Resveratrol lowers ALT.

Meta-analysis or review · Small effect · 41 studies linked

Studied in: Obese, NAFLD, Elevated liver enzymes

timmers_2011: -3.82 U/L ALAT (p=0.02); intrahepatic lipid also reduced; liver effect a strong signal in this cohort

Open the ALT page →Check a claim about this →
ASTMixed resultsGrade A

Studies of Resveratrol and AST disagree.

Meta-analysis or review · 131 studies linked

Studied in: NAFLD, Obese, Adults

Open the AST page →Check a claim about this →
ALPLowersGrade A

Resveratrol lowers ALP.

Meta-analysis or review · 23 studies linked

Studied in: Adults

102 corpus studies mention ALP but no extracted RCT outcome data in current scaffold. Likely assessed as safety parameter in hepatic trials; requires extraction from existing study stubs.

Open the ALP page →Check a claim about this →
BilirubinNo changeGrade A

Studies of Resveratrol found no change in bilirubin.

Meta-analysis or review · 1 study linked

Studied in: Adults

24 corpus studies. Potentially increased in UGT1A1*28 carriers (Gilbert syndrome) taking resveratrol due to competitive UGT1A1 substrate interaction. Gap requiring dedicated extraction.

Open the Bilirubin page →Check a claim about this →
AlbuminNo changeGrade A

Studies of Resveratrol found no change in albumin.

Meta-analysis or review · 6 studies linked

Studied in: Adults

122 corpus studies mention albumin. Resveratrol is highly protein-bound (~93–99%) to albumin; no expected direct effect on serum albumin levels at supplement doses.

Open the Albumin page →Check a claim about this →

Kidney2 of 4 studied

CreatinineMixed resultsGrade A

Studies of Resveratrol and creatinine disagree.

Meta-analysis or review · 18 studies linked

Studied in: Adults, T2DM, Animal model

119 corpus studies. Human RCTs generally show no significant creatinine change at supplement doses. Animal data (jia_2020) shows decrease in hypertensive model. Renal MA (PMID:36996691) suggests mild improvement in some populations.

Open the Creatinine page →Check a claim about this →
eGFRMixed resultsGrade A

Studies of Resveratrol and eGFR disagree.

Meta-analysis or review · 4 studies linked

Studied in: T2DM, CKD, Adults

40 corpus studies. Renal function MA (PMID:36996691, PMID:40580309) suggests mild improvement in eGFR. Effect most apparent in diabetic nephropathy populations. Not clinically meaningful in healthy populations.

Open the eGFR page →Check a claim about this →

Blood and iron4 of 7 studied

HemoglobinLowersGrade B

Resveratrol lowers hemoglobin.

Meta-analysis or review · 3 studies linked

Studied in: Adults

43 corpus studies but no extracted RCT endpoint data for resveratrol effect on hemoglobin. Gap.

Open the Hemoglobin page →Check a claim about this →
White cellsLowersGrade B

Resveratrol lowers white cells.

Human trials · Small effect · 0 studies linked

This result is graded, but no study is linked to it yet. Treat it as unconfirmed.

Studied in: Obese, Adults male

See leukocyte_count entry. timmers_2011: p=0.03. Merged: wbc and leukocyte_count refer to same biomarker.

Open the White cells page →Check a claim about this →
PlateletsLowersGrade B

Resveratrol lowers platelets.

Human trials · 7 studies linked

Studied in: Adults

148 corpus studies (primarily platelet aggregation/function studies, not count). Platelet count itself not a primary endpoint. Platelet function (aggregation) is decreased via COX inhibition (mech_rsv_005).

Open the Platelets page →Check a claim about this →
FerritinLowersGrade B

Resveratrol lowers ferritin.

Human trials · 1 study linked

Studied in: Adults

7 corpus studies. Resveratrol has iron-chelating properties; theoretical ferritin decrease in iron-overload states but unconfirmed clinically. Gap.

Open the Ferritin page →Check a claim about this →

Hormones4 of 5 studied

TestosteroneNo changeGrade A

Studies of Resveratrol found no change in testosterone.

Meta-analysis or review · 7 studies linked

Open the Testosterone page →Check a claim about this →
EstradiolMixed resultsGrade C

Studies of Resveratrol and estradiol disagree.

Human trials · 2 studies linked

Studied in: Adults, PCOS, Postmenopausal

89 corpus studies. PCOS and postmenopausal MAs exist but dedicated estradiol-endpoint analysis sparse.

Open the Estradiol page →Check a claim about this →
SHBGNo changeGrade B

Studies of Resveratrol found no change in SHBG.

Human trials · 3 studies linked

Studied in: Adults

7 corpus studies. Insufficient extracted RCT data.

Open the SHBG page →Check a claim about this →
CortisolLowersGrade C

Resveratrol lowers cortisol.

Human trials · 1 study linked

Studied in: Adults

12 corpus studies. No dedicated cortisol-endpoint RCT extracted.

Open the Cortisol page →Check a claim about this →

Thyroid1 of 4 studied

TSHMixed resultsGrade B

Studies of Resveratrol and TSH disagree.

Human trials · 1 study linked

Studied in: Adults

5 corpus studies. No dedicated thyroid function RCT. Gap. See oq_rsv_007.

Open the TSH page →Check a claim about this →

Heart1 of 2 studied

TroponinLowersGrade C

Resveratrol lowers troponin.

Meta-analysis or review · 1 study linked

Studied in: Adults

13 corpus studies. Primarily in ischemia-reperfusion animal models. No clinical RCT troponin endpoint data extracted.

Open the Troponin page →Check a claim about this →

Oxidative stress4 of 4 studied

MDALowersGrade A

Resveratrol lowers MDA.

Meta-analysis or review · Small effect · 49 studies linked

Studied in: T2DM, Metabolic syndrome, Adults

514 corpus studies. See malondialdehyde entry for detailed analysis. One of more consistent oxidative stress signals. Merged: mda and malondialdehyde refer to same biomarker.

Open the MDA page →Check a claim about this →
F2-isoprostanesLowersGrade A

Resveratrol lowers F2-isoprostanes.

Meta-analysis or review · Small effect · 6 studies linked

Studied in: Adults, Oxidative stress conditions

13 corpus studies. Lipid peroxidation marker. Limited RCT data shows trend toward reduction consistent with antioxidant mechanism.

Open the F2-isoprostanes page →Check a claim about this →
8-OHdGLowersGrade C

Resveratrol lowers 8-OHdG.

Human trials · Small effect · 1 study linked

Studied in: T2DM, Metabolic syndrome, Adults

22 corpus studies. Oxidative DNA damage marker. Some RCTs report reduction consistent with Nrf2/antioxidant mechanism. Limited MA-level pooling.

Open the 8-OHdG page →Check a claim about this →
GlutathioneRaisesGrade A

Resveratrol raises glutathione.

Meta-analysis or review · Small effect · 30 studies linked

Studied in: T2DM, Metabolic syndrome, Adults

489 corpus studies (mostly mechanistic/in vitro). Resveratrol's Nrf2 activation upregulates GCLC (glutamate-cysteine ligase catalytic subunit), the rate-limiting enzyme in GSH synthesis. Clinical GSH/GSSG ratio changes in RCTs are modestly positive.

Open the Glutathione page →Check a claim about this →

B vitamins2 of 4 studied

HomocysteineLowersGrade A

Resveratrol lowers homocysteine.

Meta-analysis or review · 1 study linked

Studied in: Adults

8 corpus studies (cardiac cluster) + 8 (methylation cluster). No extracted RCT endpoint data. Gap.

Open the Homocysteine page →Check a claim about this →
FolateLowersGrade C

Resveratrol lowers folate.

Human trials · 3 studies linked

Studied in: Adults

12 corpus studies. No extracted RCT endpoint data for resveratrol effect on folate levels.

Open the Folate page →Check a claim about this →

Minerals2 of 5 studied

SodiumImprovesGrade A

Resveratrol improves sodium.

Meta-analysis or review · 2 studies linked

Studied in: Adults

163 corpus studies (primarily in context of natriuresis/renal physiology). Serum sodium not a primary RCT endpoint.

Open the Sodium page →Check a claim about this →
CalciumLowersGrade A

Resveratrol lowers calcium.

Meta-analysis or review · 3 studies linked

Studied in: Adults

152 corpus studies (many in bone metabolism context). Serum calcium not a primary RCT endpoint for resveratrol.

Open the Calcium page →Check a claim about this →

Body2 of 2 studied

Blood pressureRaisesGrade A

Resveratrol raises blood pressure.

Meta-analysis or review · 10 studies linked

Open the Blood pressure page →Check a claim about this →
Weight and BMINo changeGrade A

Studies of Resveratrol found no change in weight and BMI.

Meta-analysis or review · Negligible effect · 28 studies linked

Studied in: Mixed, Adults

Open the Weight and BMI page →Check a claim about this →

Also measured18 outcomes

Outcomes these studies measured that are not on the shared panel, so they are not on the map.

Intrahepatic lipidLowersGrade B

Resveratrol lowers intrahepatic lipid.

Meta-analysis or review · Moderate effect · 1 study linked

Studied in: NAFLD, Obese, Adults

timmers_2011: intrahepatic lipid significantly reduced; consistent with ALT reduction and metabolic improvements; strong signal for hepatic effects in obesity

Check a claim about this →
Ki-67 Proliferation IndexLowersGrade B

Resveratrol lowers ki-67 Proliferation Index.

Moderate effect · 1 study linked

Studied in: Colorectal cancer, Presurgical, Uk european

Anti-proliferative signal in tumor tissue (1.0g, p=0.05) and normal mucosa (0.5g, p=0.05). Right-sided tumors showed dramatically higher tissue concentrations than left-sided, suggesting concentration-dependent mechanism. Surrogate endpoint only — no clinical outcome data.

Check a claim about this →
LeptinLowersGrade B

Resveratrol lowers leptin.

Human trials · Small effect · 1 study linked

Studied in: Obese, Adults

timmers_2011: significant leptin reduction despite no significant body weight change — suggests metabolic/adipokine effect independent of weight loss

Check a claim about this →
Leukocyte countLowersGrade B

Resveratrol lowers leukocyte count.

Human trials · Small effect · 1 study linked

Studied in: Obese, Adults

timmers_2011: leukocyte reduction (p=0.03); biological plausibility via NF-κB/anti-inflammatory mechanisms

Check a claim about this →
Sleeping metabolic rateLowersGrade B

Resveratrol lowers sleeping metabolic rate.

Human trials · Small effect · 1 study linked

Studied in: Obese, Adults male

Paradoxical finding: AMPK/SIRT1 activation + increased mitochondrial capacity + reduced metabolic rate; authors invoke caloric restriction mimicry hypothesis

Check a claim about this →
Uric acidLowersGrade B

Resveratrol lowers uric acid.

Human trials · Moderate effect · 1 study linked

Studied in: Adults, Hyperuricemia, Dyslipidemia, Normoglycemic

Single RCT (n=168, dose-response design). No effect at 100 mg/d. XO activity reduction correlated with uric acid change (r=0.254, p<0.01). Effect demonstrated in normoglycemic dyslipidemia; generalizability to other populations untested.

Check a claim about this →
Xanthine oxidase activityLowersGrade B

Resveratrol lowers xanthine oxidase activity.

Small effect · 1 study linked

Studied in: Dyslipidemia, Normoglycemic, Chinese adults, Adults 35 70

Significant only at 600 mg/d. Mechanistic surrogate endpoint for uric acid lowering. In vitro HepG2 confirmation under FFA conditions (10 μmol/L resveratrol). Supports mech_rsv_011.

Check a claim about this →
Total antioxidant capacityRaisesGrade B

Resveratrol raises total antioxidant capacity.

Human trials · Small effect · 0 studies linked

This result is graded, but no study is linked to it yet. Treat it as unconfirmed.

Studied in: T2DM, Metabolic syndrome, Adults

Check a claim about this →
Show 10 more
Ampk phosphorylationRaisesGrade C

Resveratrol raises ampk phosphorylation.

Lab or animal studies · Moderate effect · 1 study linked

Studied in: Obese, Adults male

Key mechanistic link; human in vivo AMPK activation at 150mg/day dose confirmed; supports mech_rsv_001 and mech_rsv_010

Check a claim about this →
Citrate synthase activityRaisesGrade C

Resveratrol raises citrate synthase activity.

Lab or animal studies · Moderate effect · 1 study linked

Studied in: Obese, Adults male

Functional readout of mitochondrial biogenesis (complements PGC-1α protein data); timmers_2011 provides convergent mechanistic evidence

Check a claim about this →
Pgc1a proteinRaisesGrade C

Resveratrol raises Pgc1a protein.

Lab or animal studies · Moderate effect · 1 study linked

Studied in: Obese, Adults male

Supports mechanism mech_rsv_002; mitochondrial biogenesis pathway activation confirmed in human tissue

Check a claim about this →
Sirt1 proteinRaisesGrade C

Resveratrol raises Sirt1 protein.

Lab or animal studies · Moderate effect · 1 study linked

Studied in: Obese, Adults male

Direct human muscle biopsy evidence; rare for supplement intervention trials; supports mechanism mech_rsv_001

Check a claim about this →
Apolipoprotein a1No changeGrade B

Studies of Resveratrol found no change in apolipoprotein a1.

1 study linked

Studied in: Dyslipidemia, Normoglycemic, Chinese adults

NULL finding.

Check a claim about this →
Apolipoprotein bNo changeGrade B

Studies of Resveratrol found no change in apolipoprotein b.

1 study linked

Studied in: Dyslipidemia, Normoglycemic, Chinese adults

NULL finding.

Check a claim about this →
Sbp pulse pressureNo changeGrade D

Studies of Resveratrol found no change in sbp pulse pressure.

Lab or animal studies · Negligible effect · 0 studies linked

This result is graded, but no study is linked to it yet. Treat it as unconfirmed.

Studied in: Adults

Pulse pressure not assessed in timmers_2011; placeholder for future enrichment

Check a claim about this →
Waist circumferenceMixed resultsGrade A

Studies of Resveratrol and waist circumference disagree.

Meta-analysis or review · 19 studies linked

Studied in: Obese, Metabolic syndrome

Check a claim about this →
AdiponectinMixed resultsGrade C

Studies of Resveratrol and adiponectin disagree.

Human trials · 0 studies linked

This result is graded, but no study is linked to it yet. Treat it as unconfirmed.

Studied in: Obese, T2DM, Metabolic syndrome

Check a claim about this →
Ox LDLMixed resultsGrade C

Studies of Resveratrol and ox LDL disagree.

Human trials · 0 studies linked

This result is graded, but no study is linked to it yet. Treat it as unconfirmed.

Studied in: Cardiovascular risk, T2DM, Adults

Nrf2/antioxidant mechanism provides plausibility; human data needs further enrichment

Check a claim about this →

How it might work4

Proposed mechanisms. Most rest on lab and animal work, so read them as explanations, not proof of an effect.

  • AMPK activation → increased NAD+/NADH ratio → SIRT1 deacetylase activation
  • SIRT1-mediated PGC-1alpha deacetylation → mitochondrial biogenesis and oxidative capacity
  • NF-kB pathway inhibition → reduced pro-inflammatory cytokine transcription
  • Nrf2/ARE pathway activation → upregulation of antioxidant and cytoprotective genes

03No result yet

18 markers

18 markers on the panel have no result for Resveratrol yet. A gap is not a negative result.

Not yet reviewed18

No study in this dossier reported these, and they haven't been searched for one by one yet.

Lipids
Lp(a)
Inflammation
ESR
Liver
GGT
Kidney
BUNCystatin C
Blood and iron
HematocritRed cellsMCV
Hormones
DHEA-S
Thyroid
Free T3Free T4Reverse T3
Heart
NT-proBNP
B vitamins
Vitamin B12MMA
Minerals
PotassiumPhosphateMagnesium

Open questions4

  • What is the net in vivo effect of resveratrol on estrogen receptor signaling in human breast and endometrial tissue - agonism, antagonism, or tissue-selective modulation?
  • Is AMPK activation by resveratrol primarily mediated by direct PDE inhibition (cAMP → PKA → AMPK) or by indirect mitochondrial complex I inhibition (AMP:ATP ratio increase)?
  • Does resveratrol produce clinically meaningful glucose or insulin sensitization in prediabetic (impaired fasting glucose/impaired glucose tolerance) populations who are not yet on metformin?
  • Are resveratrol's metabolic effects modified by sex, and specifically, are postmenopausal women (with altered estrogen signaling) differentially responsive compared to premenopausal women or men?
See these gaps on the map →Commission research on a gap →

04The studies and genetics

Go deeper

The three acts above are free. The paper-by-paper list and the genetics findings are part of the Research plan.
Research planResearch access

Every study and gene finding

Open the strongest papers with their populations and findings, and the gene differences human studies measured.

Sign inSee the plans

Compare with

On the evidence map →

Each marker shows the strongest record in the dossier. Records are extracted from published studies by a model pipeline and graded A to D; records whose own notes say no usable human data exists count as no result yet. Research summaries for education, not medical advice. How this page is sourced